IDEXX Laboratories, Inc. - 10-Q Summary (Period Ended Sept 30, 2009)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for IDEXX Laboratories, Inc., a provider of diagnostic products and services for the veterinary, water, and production animal markets. The report covers the three and nine months ended September 30, 2009. The company operates primarily through three reportable segments: Companion Animal Group (CAG), Water, and Production Animal Segment (PAS).
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sept 30, 2009 | 9 Months Ended Sept 30, 2009 |
|---|---|---|
| Total Revenue | $259,120 | $761,298 |
| Gross Profit | $130,477 | $393,350 |
| Gross Margin | 50.4% | 51.7% |
| Net Income | $31,536 | $91,274 |
| Diluted EPS | $0.52 | $1.50 |
| Operating Cash Flow (9mo) | $115,503 | |
| Cash and Equivalents (Sept 30, 2009) | $106,728 | |
| Total Debt Outstanding | $142.6 million (Revolving Credit Facility) |
Material Changes vs. Prior Period
- Revenue: Total revenue increased 3.2% for the quarter compared to the prior year, driven by a 4.7% increase in the CAG segment. However, for the nine-month period, total revenue decreased 2.5% due to a 10.9% decline in the Production Animal Segment and a 4.5% decline in the Water segment.
- Profitability: Net income for the quarter increased 22.7% to $31.5 million, while nine-month net income decreased slightly by 1.4% to $91.3 million. Operating income for the quarter rose 13.4% to $44.2 million.
- Segment Performance: The CAG segment saw growth in instruments, consumables, and laboratory services, offset by the divestiture of pharmaceutical products. The PAS segment faced significant headwinds from reduced testing volumes due to economic conditions and lower government funding for eradication programs.
- Acquisitions: The company acquired VDIC, Inc. and Pet Detect in August 2009 for approximately $6.7 million in cash and $1.2 million in liabilities, adding telemedicine and pet identification capabilities.
Outlook, Risks, and Management Commentary
- Economic Impact: Management notes that weaker economic conditions have reduced patient visits to veterinary clinics and increased customer price sensitivity, negatively impacting sales of rapid assays and capital instruments. Similar trends are affecting the Water and PAS segments.
- Foreign Currency: A strengthening U.S. dollar negatively impacted international revenues and margins. Approximately 23% of revenue is derived from products manufactured in the U.S. and sold internationally.
- Liquidity: The company maintains a strong liquidity position with $106.7 million in cash and $56.8 million remaining availability under its credit facility. Working capital increased significantly due to the reclassification of $80 million of debt to long-term liabilities.
- Capital Allocation: The company continued its share repurchase program, buying back approximately 1.5 million shares in the first nine months of 2009. Capital expenditures were reduced compared to the prior year, primarily due to a slowdown in the headquarters renovation project.
- Risks: Key risks include dependence on a limited number of suppliers, potential disruption in financial markets, and the impact of a weak economy on discretionary pet care spending.
Investor Verification Checklist
- Segment Mix: Verify the sustainability of CAG growth given the divestiture of pharmaceutical assets and the continued decline in the PAS segment.
- Distributor Inventory: Assess the impact of distributor purchasing dynamics versus actual end-user demand, particularly in the CAG segment.
- Debt Structure: Confirm the terms and covenants of the revolving credit facility, noting the reclassification of $80 million to long-term debt.
- Foreign Exchange: Monitor the impact of the strengthening U.S. dollar on future margins and revenue growth.
- Acquisition Integration: Review the financial contribution of the VDIC and Pet Detect acquisitions in subsequent quarters.